Global Agoraphobia Treatment Market
Global Agoraphobia Treatment Market

Agoraphobia Treatment Comprehensive Study by Application (Hospitals, Specialty Clinic Center, Others), Therapy (Psychotherapy, Cognitive Behavioral Therapy (CBT), Exposure Therapy, Other), Medication (Antidepressants, Anti-anxiety medication, Other), Agoraphobia Symptoms (Panic Disorder, Chest Pain, Dizziness, Hyperhidrosis, Upset Stomach) Players and Region - Global Market Outlook to 2026

Agoraphobia Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 207 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Agoraphobia Treatment Market Scope
Agoraphobia treatment usually includes both psychotherapy and medication. A specific form of psychotherapy that focuses on decreasing negative, anxiety-provoking, or other self-defeating thoughts and behaviors has been found to be highly effective in treating agoraphobia. Another form of therapy that has been found effective in managing agoraphobia includes self-exposure. In that intervention, people either imagine or put themselves into situations that cause increased levels of agoraphobic anxiety, using relaxation techniques in each situation in order to master their anxiety.

The Agoraphobia Treatment market study is segmented, by Application (Hospitals, Specialty Clinic Center and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Psych Central (United States), Bristol-Myers Squibb (United States), Johnson & Johnson (United States), Sandoz Inc. (Germany), Eli Lilly & Co. (United States), Apotex Corp. (Canada), Mylan Pharmaceuticals Inc. (Unite States), Glaxosmithkline plc. (United Kingdom), Pfizer Inc. (United States) and AstraZeneca (United Kingdom) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Agoraphobia Treatment market by Type, Application and Region.

On the basis of geography, the market of Agoraphobia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Rapidly Development In Treatment Of Agoraphobia

Market Drivers
  • Prevalence Of Panic Attacks And Other Phobias

Opportunities
  • High Governmental Healthcare Expenditure

Restraints
  • Limitations Of Existing Research

Challenges
  • Technical Complexities Related To Agoraphobia Treatment


Key Target Audience
Agoraphobia Treatment Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Agoraphobia Treatment Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Specialty Clinic Center
  • Others
By Therapy
  • Psychotherapy
  • Cognitive Behavioral Therapy (CBT)
  • Exposure Therapy
  • Other

By Medication
  • Antidepressants
  • Anti-anxiety medication
  • Other

By Agoraphobia Symptoms
  • Panic Disorder
  • Chest Pain
  • Dizziness
  • Hyperhidrosis
  • Upset Stomach

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence Of Panic Attacks And Other Phobias
    • 3.3. Market Challenges
      • 3.3.1. Technical Complexities Related To Agoraphobia Treatment
    • 3.4. Market Trends
      • 3.4.1. Rapidly Development In Treatment Of Agoraphobia
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Agoraphobia Treatment, by Application, Therapy, Medication, Agoraphobia Symptoms and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Agoraphobia Treatment (Value)
      • 5.2.1. Global Agoraphobia Treatment by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Specialty Clinic Center
        • 5.2.1.3. Others
      • 5.2.2. Global Agoraphobia Treatment by: Therapy (Value)
        • 5.2.2.1. Psychotherapy
        • 5.2.2.2. Cognitive Behavioral Therapy (CBT)
        • 5.2.2.3. Exposure Therapy
        • 5.2.2.4. Other
      • 5.2.3. Global Agoraphobia Treatment by: Medication (Value)
        • 5.2.3.1. Antidepressants
        • 5.2.3.2. Anti-anxiety medication
        • 5.2.3.3. Other
      • 5.2.4. Global Agoraphobia Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Agoraphobia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Psych Central (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sandoz Inc. (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly & Co. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Apotex Corp. (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan Pharmaceuticals Inc. (Unite States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Glaxosmithkline plc. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Agoraphobia Treatment Sale, by Application, Therapy, Medication, Agoraphobia Symptoms and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Agoraphobia Treatment (Value)
      • 7.2.1. Global Agoraphobia Treatment by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Specialty Clinic Center
        • 7.2.1.3. Others
      • 7.2.2. Global Agoraphobia Treatment by: Therapy (Value)
        • 7.2.2.1. Psychotherapy
        • 7.2.2.2. Cognitive Behavioral Therapy (CBT)
        • 7.2.2.3. Exposure Therapy
        • 7.2.2.4. Other
      • 7.2.3. Global Agoraphobia Treatment by: Medication (Value)
        • 7.2.3.1. Antidepressants
        • 7.2.3.2. Anti-anxiety medication
        • 7.2.3.3. Other
      • 7.2.4. Global Agoraphobia Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Agoraphobia Treatment: by Application(USD Million)
  • Table 2. Agoraphobia Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 3. Agoraphobia Treatment Specialty Clinic Center , by Region USD Million (2015-2020)
  • Table 4. Agoraphobia Treatment Others , by Region USD Million (2015-2020)
  • Table 5. Agoraphobia Treatment: by Therapy(USD Million)
  • Table 6. Agoraphobia Treatment Psychotherapy , by Region USD Million (2015-2020)
  • Table 7. Agoraphobia Treatment Cognitive Behavioral Therapy (CBT) , by Region USD Million (2015-2020)
  • Table 8. Agoraphobia Treatment Exposure Therapy , by Region USD Million (2015-2020)
  • Table 9. Agoraphobia Treatment Other , by Region USD Million (2015-2020)
  • Table 10. Agoraphobia Treatment: by Medication(USD Million)
  • Table 11. Agoraphobia Treatment Antidepressants , by Region USD Million (2015-2020)
  • Table 12. Agoraphobia Treatment Anti-anxiety medication , by Region USD Million (2015-2020)
  • Table 13. Agoraphobia Treatment Other , by Region USD Million (2015-2020)
  • Table 14. South America Agoraphobia Treatment, by Country USD Million (2015-2020)
  • Table 15. South America Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 16. South America Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 17. South America Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 18. South America Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 19. Brazil Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 20. Brazil Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 21. Brazil Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 22. Brazil Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 23. Argentina Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 24. Argentina Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 25. Argentina Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 26. Argentina Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 27. Rest of South America Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 29. Rest of South America Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 30. Rest of South America Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 31. Asia Pacific Agoraphobia Treatment, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 34. Asia Pacific Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 35. Asia Pacific Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 36. China Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 37. China Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 38. China Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 39. China Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 40. Japan Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 41. Japan Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 42. Japan Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 43. Japan Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 44. India Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 45. India Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 46. India Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 47. India Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 48. South Korea Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 49. South Korea Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 50. South Korea Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 51. South Korea Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 52. Taiwan Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 53. Taiwan Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 54. Taiwan Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 55. Taiwan Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 56. Australia Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 57. Australia Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 58. Australia Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 59. Australia Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 64. Europe Agoraphobia Treatment, by Country USD Million (2015-2020)
  • Table 65. Europe Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 66. Europe Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 67. Europe Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 68. Europe Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 69. Germany Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 70. Germany Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 71. Germany Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 72. Germany Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 73. France Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 74. France Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 75. France Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 76. France Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 77. Italy Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 78. Italy Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 79. Italy Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 80. Italy Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 81. United Kingdom Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 82. United Kingdom Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 83. United Kingdom Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 84. United Kingdom Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 85. Netherlands Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 86. Netherlands Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 87. Netherlands Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 88. Netherlands Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 89. Rest of Europe Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 90. Rest of Europe Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 91. Rest of Europe Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 92. Rest of Europe Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 93. MEA Agoraphobia Treatment, by Country USD Million (2015-2020)
  • Table 94. MEA Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 95. MEA Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 96. MEA Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 97. MEA Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 98. Middle East Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 99. Middle East Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 100. Middle East Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 101. Middle East Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 102. Africa Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 103. Africa Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 104. Africa Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 105. Africa Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 106. North America Agoraphobia Treatment, by Country USD Million (2015-2020)
  • Table 107. North America Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 108. North America Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 109. North America Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 110. North America Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 111. United States Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 112. United States Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 113. United States Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 114. United States Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 115. Canada Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 116. Canada Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 117. Canada Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 118. Canada Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 119. Mexico Agoraphobia Treatment, by Application USD Million (2015-2020)
  • Table 120. Mexico Agoraphobia Treatment, by Therapy USD Million (2015-2020)
  • Table 121. Mexico Agoraphobia Treatment, by Medication USD Million (2015-2020)
  • Table 122. Mexico Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2015-2020)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Agoraphobia Treatment: by Application(USD Million)
  • Table 134. Agoraphobia Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 135. Agoraphobia Treatment Specialty Clinic Center , by Region USD Million (2021-2026)
  • Table 136. Agoraphobia Treatment Others , by Region USD Million (2021-2026)
  • Table 137. Agoraphobia Treatment: by Therapy(USD Million)
  • Table 138. Agoraphobia Treatment Psychotherapy , by Region USD Million (2021-2026)
  • Table 139. Agoraphobia Treatment Cognitive Behavioral Therapy (CBT) , by Region USD Million (2021-2026)
  • Table 140. Agoraphobia Treatment Exposure Therapy , by Region USD Million (2021-2026)
  • Table 141. Agoraphobia Treatment Other , by Region USD Million (2021-2026)
  • Table 142. Agoraphobia Treatment: by Medication(USD Million)
  • Table 143. Agoraphobia Treatment Antidepressants , by Region USD Million (2021-2026)
  • Table 144. Agoraphobia Treatment Anti-anxiety medication , by Region USD Million (2021-2026)
  • Table 145. Agoraphobia Treatment Other , by Region USD Million (2021-2026)
  • Table 146. South America Agoraphobia Treatment, by Country USD Million (2021-2026)
  • Table 147. South America Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 148. South America Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 149. South America Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 150. South America Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 151. Brazil Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 152. Brazil Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 153. Brazil Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 154. Brazil Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 155. Argentina Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 156. Argentina Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 157. Argentina Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 158. Argentina Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 159. Rest of South America Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 160. Rest of South America Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 161. Rest of South America Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 162. Rest of South America Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 163. Asia Pacific Agoraphobia Treatment, by Country USD Million (2021-2026)
  • Table 164. Asia Pacific Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 165. Asia Pacific Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 166. Asia Pacific Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 167. Asia Pacific Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 168. China Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 169. China Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 170. China Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 171. China Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 172. Japan Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 173. Japan Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 174. Japan Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 175. Japan Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 176. India Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 177. India Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 178. India Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 179. India Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 180. South Korea Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 181. South Korea Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 182. South Korea Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 183. South Korea Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 184. Taiwan Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 185. Taiwan Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 186. Taiwan Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 187. Taiwan Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 188. Australia Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 189. Australia Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 190. Australia Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 191. Australia Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 192. Rest of Asia-Pacific Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 193. Rest of Asia-Pacific Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 194. Rest of Asia-Pacific Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 195. Rest of Asia-Pacific Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 196. Europe Agoraphobia Treatment, by Country USD Million (2021-2026)
  • Table 197. Europe Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 198. Europe Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 199. Europe Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 200. Europe Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 201. Germany Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 202. Germany Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 203. Germany Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 204. Germany Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 205. France Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 206. France Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 207. France Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 208. France Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 209. Italy Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 210. Italy Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 211. Italy Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 212. Italy Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 213. United Kingdom Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 214. United Kingdom Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 215. United Kingdom Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 216. United Kingdom Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 217. Netherlands Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 218. Netherlands Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 219. Netherlands Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 220. Netherlands Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 221. Rest of Europe Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 222. Rest of Europe Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 223. Rest of Europe Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 224. Rest of Europe Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 225. MEA Agoraphobia Treatment, by Country USD Million (2021-2026)
  • Table 226. MEA Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 227. MEA Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 228. MEA Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 229. MEA Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 230. Middle East Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 231. Middle East Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 232. Middle East Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 233. Middle East Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 234. Africa Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 235. Africa Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 236. Africa Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 237. Africa Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 238. North America Agoraphobia Treatment, by Country USD Million (2021-2026)
  • Table 239. North America Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 240. North America Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 241. North America Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 242. North America Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 243. United States Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 244. United States Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 245. United States Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 246. United States Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 247. Canada Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 248. Canada Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 249. Canada Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 250. Canada Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 251. Mexico Agoraphobia Treatment, by Application USD Million (2021-2026)
  • Table 252. Mexico Agoraphobia Treatment, by Therapy USD Million (2021-2026)
  • Table 253. Mexico Agoraphobia Treatment, by Medication USD Million (2021-2026)
  • Table 254. Mexico Agoraphobia Treatment, by Agoraphobia Symptoms USD Million (2021-2026)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Agoraphobia Treatment: by Application USD Million (2015-2020)
  • Figure 5. Global Agoraphobia Treatment: by Therapy USD Million (2015-2020)
  • Figure 6. Global Agoraphobia Treatment: by Medication USD Million (2015-2020)
  • Figure 7. South America Agoraphobia Treatment Share (%), by Country
  • Figure 8. Asia Pacific Agoraphobia Treatment Share (%), by Country
  • Figure 9. Europe Agoraphobia Treatment Share (%), by Country
  • Figure 10. MEA Agoraphobia Treatment Share (%), by Country
  • Figure 11. North America Agoraphobia Treatment Share (%), by Country
  • Figure 12. Global Agoraphobia Treatment share by Players 2020 (%)
  • Figure 13. Global Agoraphobia Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Agoraphobia Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Psych Central (United States) Revenue, Net Income and Gross profit
  • Figure 17. Psych Central (United States) Revenue: by Geography 2020
  • Figure 18. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 20. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 22. Sandoz Inc. (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Sandoz Inc. (Germany) Revenue: by Geography 2020
  • Figure 24. Eli Lilly & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Eli Lilly & Co. (United States) Revenue: by Geography 2020
  • Figure 26. Apotex Corp. (Canada) Revenue, Net Income and Gross profit
  • Figure 27. Apotex Corp. (Canada) Revenue: by Geography 2020
  • Figure 28. Mylan Pharmaceuticals Inc. (Unite States) Revenue, Net Income and Gross profit
  • Figure 29. Mylan Pharmaceuticals Inc. (Unite States) Revenue: by Geography 2020
  • Figure 30. Glaxosmithkline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Glaxosmithkline plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 32. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 34. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 36. Global Agoraphobia Treatment: by Application USD Million (2021-2026)
  • Figure 37. Global Agoraphobia Treatment: by Therapy USD Million (2021-2026)
  • Figure 38. Global Agoraphobia Treatment: by Medication USD Million (2021-2026)
  • Figure 39. South America Agoraphobia Treatment Share (%), by Country
  • Figure 40. Asia Pacific Agoraphobia Treatment Share (%), by Country
  • Figure 41. Europe Agoraphobia Treatment Share (%), by Country
  • Figure 42. MEA Agoraphobia Treatment Share (%), by Country
  • Figure 43. North America Agoraphobia Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Psych Central (United States)
  • Bristol-Myers Squibb (United States)
  • Johnson & Johnson (United States)
  • Sandoz Inc. (Germany)
  • Eli Lilly & Co. (United States)
  • Apotex Corp. (Canada)
  • Mylan Pharmaceuticals Inc. (Unite States)
  • Glaxosmithkline plc. (United Kingdom)
  • Pfizer Inc. (United States)
  • AstraZeneca (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation